AbbVie's Rinvoq Bolsters Its Potential In Atopic Dermatitis

JAK1 Inhibitor ‘Clears’ Second Of Three Phase III AD Trials

 
• By Sten Stovall

AbbVie's Rinvoq has performed well in the second of three Phase III studies evaluating its potential treatment for atopic dermatitis, further boosting chances the JAK1 inhibitor will become a blockbuster in that indication.

Steps
Late Stage Measure Up 2 study was second of three assessing Rinvoq in AD • Source: Shutterstock

More from Business

More from Scrip